Standard-versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization

Transfusion

Volumn 50, Issue 11, 2010, Pages 2432-2446

  Romeo, Azzurra ^a,b,c,d,e   Chierichini, Anna ^a,b,c,d,e   Spagnoli, Alessandra ^a,b,c,d,e   Vittori, Mariangela ^a,b,c,d,e   Vacca, Michele ^a,b,c,d,e   Gozzer, Maria ^a,b,c,d,e   Spadea, Antonio ^a,b,c,d,e   Anaclerico, Barbara ^a,b,c,d,e   Dessanti, Maria Laura ^a,b,c,d,e   D'Andrea, Mariella ^a,b,c,d,e   Toglia, Giuseppe ^a,b,c,d,e   Annino, Luciana ^a,b,c,d,e   Petti, Maria Concetta ^a,b,c,d,e   Mengarelli, Andrea ^a,b,c,d,e   Arcese, William ^a,b,c,d,e  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; B CELL LYMPHOMA; BLASTIC NK CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTICENTER STUDY; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; T CELL LYMPHOMA;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78349239202     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02723.x     Document Type: Article

References (90)

1. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A,. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353 -7.
2. Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, Oettle H, Serke S, Huhn D, Stieger W,. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995; 13: 1328 -35.
3. Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F, Janvier M, Pico JL, Baranzelli MC, Rubie H, Coze C, Pinna A, Méresse V, Benhamou E,. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600 -7.
4. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G,. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580 -5.
5. Bensinger W, Singer J, Appelbaum FR, Lilleby K, Longin K, Rowley S, Clarke E, Clift R, Hansen J, Shields T, Storb R, Weaver C, Weiden P, Buckner CD,. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158 -63.
6. Sheridan WP, Begley CG, To LB, Grigg A, Szer J, Maher D, Green MD, Rowlings PA, McGrath KM, Cebon J, Dyson P, Watson D, Bayly J, De Luca E, Tomita D, Hoffman E, Morstyn G, Juttner CA, Fox RM,. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14: 105 -11.
7. To LB, Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D, Ho JQ, Dart GW, Horvath N, Davy ML, Olweny CLM, Abdi E, Juttner CA,. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277 -84.
8. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM,. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640 -4.
9. Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH,. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5 -10.
10. Ager S, Scott MA, Mahendra P, Richards EM, Jestice HK, Boraks P, Baglin TP, Marcus RE,. Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplant 1995; 16: 79 -83.
11. Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM,. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905 -14.
12. Dhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D,. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074 -81.
13. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD,. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194 -8.
14. Takeyama K, Ogura M, Morishima Y, Kasai M, Kiyama Y, Ohnishi K, Mitsuya H, Kawano F, Masaki Y, Sasaki T, Chou T, Yokozawa T, Tobinai K,; Lenograstim/Lymphoma Study Group. A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Jpn J Clin Oncol 2003; 33: 78 -85.
15. Narabayashi M Takeyama K, Fukutomi T, Tokuda Y, Tajima T, Okumura A, Chou T, Sano M, Makino H, Igarashi T, Sasaki Y, Imoto S, Ogura M, Morishima Y, Murai H, Okamoto S, Ikeda T, Kasai M, Yokozawa T, Tobinai K,; Lenograstim/Breast Cancer Study Group. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Jpn J Clin Oncol 1999; 29: 285 -90.
16. Blade J, Samson D, Reece D, Apperley J, Bjrkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D,; Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115 -23.
17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP,; NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244 -53.
18. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V,; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579 -86.
19. Cheson BD, Bennett JM, Kopecky KJ, B chner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, L wenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD,; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642 -9.
20. Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P,. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci 2009; 41: 33 -7.
21. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, Zangari M, Anaissie E, Tricot G,. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413 -23.
22. Ikeda K, Kozuka T, Harada M,. Factors for PBPC collection efficiency and collection predictors. Transfus Apher Sci 2004; 31: 245 -59.
23. De La Rubia J, Bladé J, Lahuerta JJ, Ribera JM, Martínez R, Alegre A, García-Laraña J, Fernández P, Sureda A, De Arriba F, Carrera D, Besalduch J, García Boyero R, Palomera Bernal L, Hernández MT, García PR, Pérez-Calvo J, Alcalá A, Casado LF, San Miguel J,. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica 2006; 91: 621 -7.
24. Dreger P, Klss M, Petersen B, Haferlach T, L ffler H, Loeffler M, Schmitz N,. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970 -8.
25. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C,. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547 -55.
26. Haas R, Mhle R, Frhauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W,. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787 -94.
27. Kobbe G, Shngen D, Bauser U, Schneider P, Germing U, Thiele KP, Rieth C, Hnerlit rkoglu A, Fischer J, Frick M, Wernet P, Aul C, Heyll A,. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma. Ann Hematol 1999; 78: 456 -62.
28. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B,. Peripheral blood stem cell transplants for multiple myeloma: identification of favourable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588 -96.
29. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD,. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311 -6.
30. Gertz MA, Lacy MQ, Inwards DJ, Pineda AA, Chen MG, Gastineau DA, Tefferi A, Kyle RA, Litzow MR,. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1997; 20: 375 -80.
31. Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L, Rus C, Bertola A, Giaccone L, Omed P, Musto P,. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846 -50.
32. Weaver CH, Zhen B, Buckner CD,. Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells. Bone Marrow Transplant 1998; 21: 1169 -70.
33. Canales MA, Fernández-Jiménez MC, Martín A, Arrieta R, Caballero MD, Díez J, Quevedo E, García-Bustos J, San Miguel JF, Hernández-Navarro F,. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 2001; 86: 494 -8.
34. Ford CD, Green W, Warenski S, Petersen FB,. Effect of prior chemotherapy on hematopoietic stem cell mobilization. Bone Marrow Transplantation 2004; 33: 901 -5.
35. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R,. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736 -44.
36. Gandhi MK, Jestice K, Scott MA, Bloxham D, Bass G, Marcus RE,. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9 -13.
37. Weaver CH, Schwartzberg LS, Birch R, Greco FA, Rhinehart S, Hainsworth J, Beeker T, Price H, Geier L, Foster J, West J, Hazelton B, Buckner CD,. Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients. Transfusion 1997; 37: 896 -903.
38. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P, Thieblemont C, Durand B, Neidhardt-Berard EM, Samaha H, Rigal D, Coiffier B,. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235 -42.
39. Carral A, De La Rubia J, Martín G, Mollá S, Martínez J, Sanz GF, Soler MA, Jarque I, Jiménez C, Sanz MA,. Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. Leuk Res 2003; 27: 5 -12.
40. Tarella C, Zallio F, Caracciolo D, Cherasco C, Bondesan P, Gavarotti P, Corradini P, Tassi V, Pileri A,. Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients. Stem Cells 1999; 17: 55 -61.
41. Perry AR, Watts MJ, Peniket AJ, Goldstone AH, Linch DC,. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant 1998; 21: 1201 -5.
42. Kuittinen T, Nousiainen T, Halonen P, Mahlamki E, Jantunen E,. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907 -12.
43. Michallet M, Thiébaut A, Dreger P, Remes K, Milpied N, Santini G, Hamon M, Bjrkstrand B, Kimby E, Belhabri A, Tanguy ML, Apperley JF,. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemia Working Party (CLWP). Br J Haematol 2000; 108: 595 -601.
44. Montillo M, Tedeschi A, Rossi V, Cairoli R, Pungolino E, Intropido L, Cafro AM, D'Avanzo G, Farioli R, Brando B, Scarpati B, Veronese S, Morra E,. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia 2004; 18: 57 -62.
45. Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T, Piantadosi S, Seifter E, Ambinder RF, Vogelsang G, Grever MR,. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71 -5.
46. It M, Pelliniemi TT, Rajamki A, Remes K,. Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplant 1997; 19: 647 -51.
47. Laszlo D, Galieni P, Raspadori D, Scalia G, Bigazzi C, Bocchia M, Bucalossi A, Marotta G, Tozzi M, Lauria F,. Fludarabine-containing regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma 2000; 37: 157 -61.
48. Eve HE, Seymour JF, Rule SA,. Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/-rituximab. Leuk Lymphoma 2009; 50: 463 -5.
49. Lysak D, Koza V, Steinerova K, Jindra P, Vozobulova V, Schutzova M,. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment. Ann Hematol 2005; 84: 456 -61.
50. Tournilhac O, Cazin B, Leprtre S, Diviné M, Maloum K, Delmer A, Grosbois B, Feugier P, Maloisel F, Villard F, Villemagne B, Bastit D, Belhadj K, Azar N, Michallet M, Manhs G, Travade P,. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363 -5.
51. Jantunen E, It M, Siitonen T, Kuittinen T, Heiskanen J, Koivunen E, Juvonen E, Silvennoinen R, Nousiainen T, Koistinen P, Volin L, Remes K,. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. Bone Marrow Transplantation 2008; 41: 239 -44.
52. Visani G, Lemoli RM, Tosi P, Martinelli G, Testoni N, Ricci P, Piccaluga PP, Pastano R, Leopardi G, Dizdari A, Motta MR, Rizzi S, Tura S,. Fludarabine-containing regimens severely impair peripheral blood stem cell mobilization and collection in acute myeloid leukemia patients. Br J Haematol 1999; 105: 775 -9.
53. Robak T,. Purine nucleoside analogues in the treatment of myleoid leukemias. Leuk Lymphoma 2003; 44: 391 -409.
54. Visani G, Lemoli RM, Isidori A, Piccaluga PP, Martinelli G, Malagola M, Gugliotta L, Bonini A, Bonifazi F, Motta MR, Rizzi S, Castellani S, Tura S,. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients. Bone Marrow Transplant 2001; 27: 829 -35.
55. Russo D, Pricolo G, Michieli M, Michelutti A, Raspadori D, Bertone A, Marin L, Pierri I, Bucalossi A, Zuffa E, De Vivo A, Mazza P, Gobbi M, Lauria F, Zaccaria A, Baccarani M,. Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia. Leuk Lymphoma 2001; 40: 335 -43.
56. Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ,. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006; 134: 517 -25.
57. Fischer JC, Frick M, Wassmuth R, Platz A, Punzel M, Wernet P,. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol 2005; 130: 740 -6.
58. Hglund M, Smedmyr B, Bengtsson M, Ttterman TH, Cour-Chabernaud V, Yver A, Simonsson B,. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers-a comparative study. Eur J Haematol 1997; 59: 177 -83.
59. Watts MJ, Addison I, Long SG, Hartley S, Warrington S, Boyce M, Linch DC,. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 1997; 98: 474 -9.
60. Kuwabara T, Kato Y, Kobayashi S, Suzuki H, Sugiyama Y,. Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): species differences among rats, monkeys and humans. J Pharmacol Exp Ther 1994; 271: 1535 -43.
61. Kuwabara T, Kobayashi S, Sugiyama Y,. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev 1996; 28: 625 -58.
62. Hayashi N, Kinoshita H, Yukawa E, Higuchi S,. Pharmacokinetic and pharmacodynamic analysis of subcutaneous recombinant human granulocyte colony stimulating factor (lenograstim) administration. J Clin Pharmacol 1999; 39: 583 -92.
63. Hunter MG, Druhan LJ, Massullo PR, Avalos BR,. Proteolytic cleavage of granulocyte colony-stimulating factor and its receptor by neutrophil elastase induces growth inhibition and decreased cell surface expression of the granulocyte colony-stimulating factor receptor. Am J Hematol 2003; 74: 149 -55.
64. El Ouriaghli F, Fujiwara H, Melenhorst JJ, Sconocchia G, Hensel N, Barrett AJ,. Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. Blood 2003; 101: 1752 -8.
65. Ono M,. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim). Eur J Cancer 1994; 30A Suppl 3: S7 -11.
66. Carter CR, Whitmore KM, Thorpe R,. The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol 2004; 75: 515 -22.
67. Carter CR, Keeble JR, Thorpe R,. Human serum inactivates non-glycosylated but not glycosylated granulocyte colony stimulating factor by a protease dependent mechanism: significance of carbohydrates on the glycosylated molecule. Biologicals 2004; 32: 37 -47.
68. Dunn CJ, Goa KL,. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 2000; 59: 681 -717.
69. Hglund M, Smedmyr B, Simonsson B, Ttterman T, Bengtsson M,. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant 1996; 18: 19 -27.
70. Houston AC, Stevens LA, Cour V,. Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers. Br J Clin Pharmacol 1999; 47: 279 -84.
71. Akizuki S, Mizorogi F, Inoue T, Sudo K, Ohnishi A,. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects. Bone Marrow Transplant 2000; 26: 939 -46.
72. Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M, Buckner CD, Hansen JA, Ritz J, Appelbaum FR, Armitage JO, Nadler LM,. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773 -8.
73. Rabinowe SN, Nemunaitis J, Armitage J, Nadler LM,. The impact of myeloid growth factors on engraftment following autologous bone marrow transplantation for malignant lymphoma. Semin Hematol 1991; 28 Suppl 2: 6 -16.
74. Rabinowe SN, Neuberg D, Bierman PJ, Vose JM, Nemunaitis J, Singer JW, Freedman AS, Mauch P, Demetri G, Onetto N, Gillis S, Oette D, Buckner D, Hansen JA, Ritz J, Armitage JO, Nadler LM, Appelbaum FR,. Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993; 81: 1903 -8.
75. Shimazaki C, Oku N, Uchiyama H, Yamagata N, Tatsumi T, Hirata T, Ashihara E, Okawa K, Goto H, Inaba T, Fujita N, Haruyama H, Nakagawa M,. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1994; 13: 271 -5.
76. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS,. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective randomized trial. J Clin Oncol 1995; 13: 1323 -7.
77. Tarella C, Castellino C, Locatelli F, Caracciolo D, Corradini P, Falda M, Novarino A, Tassi V, Pileri A,. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998; 21: 401 -7.
78. Lee SM, Radford JA, Dobson L, Huq T, Ryder WD, Pettengell R, Morgenstern GR, Scarffe JH, Crowther D,. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998; 77: 1294 -9.
79. Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS, Bowers CE, Kronmueller N, Niemeyer R, McIntyre W,. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661 -70.
80. Kawano Y, Takaue Y, Mimaya J, Horikoshi Y, Watanabe T, Abe T, Shimizu Y, Matsushita T, Kikuta A, Watanabe A, Iwai A, Ito E, Endo M, Kodani N, Ohta S, Gushi K, Azuma H, Etoh T, Okamoto Y, Amano K, Hattori H, Eguchi H, Kuroda Y,; The Japanese Cooperative Study Group of PBSCT. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. Blood 1998; 92: 4040 -6.
81. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L,. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207 -15.
82. Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, DiPersio J, Rondon G, Champlin R, Barnett MJ, Cornetta K, Herzig GP, Vaughan W, Geils G Jr, Keating A, Messner H, Wolff SN, Miller KB, Linker C, Cairo M, Hellmann S, Ashby M, Stryker S, Nash RA,. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998; 91: 3509 -17.
83. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W,. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961 -9.
84. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC,; American Society of Clinical Oncology. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187 -205.
85. Kobbe G, Bruns I, Fenk R, Czibere A, Haas R,. Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant 2009; 43: 669 -77.
86. Ballestrero A, Boy D, Gonella R, Miglino M, Clavio M, Barbero V, Nencioni A, Gobbi M, Patrone F,. Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol 2008; 87: 49 -55.
87. Martino M, Pratic G, Messina G, Irrera G, Massara E, Messina G, Console G, Iacopino P,. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006; 77: 410 -5.
88. Vanstraelen G, Frre P, Ngirabacu MC, Willems E, Fillet G, Beguin Y,. Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 2006; 34: 382 -8.
89. Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL, Chen H, Schuening FG,. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 2005; 35: 1165 -9.
90. Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P,. Fixed-dose single administration of pegfilgrastim vs. daily filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005; 35: 889 -93.